Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 11:35:14 2024-07-19 am EDT 5-day change 1st Jan Change
109.3 EUR -1.18% Intraday chart for Ipsen -2.06% +1.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CAC40: maintains gains after reassuring US inflation figures CF
CAC40: rise without volume, W-Street at its zenith but falls back CF
CAC40: over 7600pts before US inflation figures CF
Ipsen: worldwide licensing agreement with Foreseen CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate MT
Markets Powered by Alternating Current Our Logo
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China MT
Ipsen Expands Partnership with Exelixis for Cabometyx MT
Ipsen extends collaboration with Exelixis CF
IPSEN : UBS remains positive ahead of quarterly results CF
Ipsen: share price soars, UBS confirms its recommendation CF
IPSEN : UBS remains Buy after FDA approval CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis CI
Ipsen: FDA grants approval for treatment CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug RE
US FDA approves Genfit and Ipsen's liver disease drug RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics MT
Ipsen: research partnership with Marengo extended CF
Ipsen Hires New Chief Corporate Affairs Officer MT
Ipsen: new Chief Corporate Affairs Officer CF
Ipsen: new positive data in PBC CF
Ipsen: mandate to an ISP for share buybacks CF
Chart Ipsen
More charts
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
109.3 EUR
Average target price
127.3 EUR
Spread / Average Target
+16.45%
Consensus
  1. Stock Market
  2. Equities
  3. IPN Stock
  4. News Ipsen
  5. Ipsen Hires New Chief Corporate Affairs Officer